The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria B ...

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / ...

The average American woman weighs about 170 pounds and stands about 5 feet, 4 inches tall. But it’s important to remember ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers ...

While alcohol use on a GLP-1 may be okay, the choice carries some theoretical risks, including reduced weight loss potential and possibly worsened side effects of GLP-1s. For those reasons ...

Investigational once-weekly retatrutide yielded the greatest weight loss of all GLP-1 receptor agonists, up to 22.1% after 48 ...

With glucagon-like peptide 1 ... weight loss, rather than an independent effect of GLP-1 RAs, according to a 2024 analysis in The Lancet Diabetes & Endocrinology. Caissa Troutman, MD By comparison ...